FDA draft guidance aims to give companies leeway to address medical misinformation
Regulatory NewsFerdous Al-Faruque
Diagnostics/IVDsGuidanceMedical DevicesPharmaceuticalsRegulatory Intelligence/PolicySafety communicationUnited StatesUS Food and Drug Administration (FDA)